Search
Search
About
Log in
Join
Experiences with
Idelalisib
Posts
Communities
142 public posts
Filter results
Updated clinical data may significantly impact treatment of CLL - Jeff Sharman
Here he discusses the impact of
idelalisib
and ibrutinib on the treatment of relapsed patients and the relevance of FCR treatment in the older population: http://www.healio.com/hematology-oncology/hematologic-malignancies/news/online/%7B4c46250f-c7dd-4acc-a87c-026815e5ab13%7D/updated-clinical-data-may-significantly-impact-impact-treatment-of-cll
Here he discusses the impact of
idelalisib
and ibrutinib on the treatment of relapsed patients and the relevance of FCR treatment in the older population: http://www.healio.com/hematology-oncology/hematologic-malignancies/news/online/%7B4c46250f-c7dd-4acc-a87c-026815e5ab13%7D/updated-clinical-data-may-significantly-impact-impact-treatment-of-cll
AussieNeil
Partner
in
CLL Support
10 years ago
ESH 2014: Prof. Stephan Stilgenbauer Reviews Predictive and Prognostic Markers in CLL
On my blog, http://bkoffman.blogspot.com , Professor Stilgenbauer reviews how the significance of predictive and prognostic factors may differ in the world of chemo-immunotherapy versus the novel therapies such as ibrutinib or
idelalisib
.
On my blog, http://bkoffman.blogspot.com , Professor Stilgenbauer reviews how the significance of predictive and prognostic factors may differ in the world of chemo-immunotherapy versus the novel therapies such as ibrutinib or
idelalisib
.
bkoffman
CLL CURE Hero
in
CLL Support
10 years ago
Long-Term Data for Zydelig (idelalisib) from ASH2014
Skip down to the section titled
Long-Term Data in CLL
, Includes information on Study 116/117 and the boxed warning (safety information) for
idelalisib
: http://www.finances.com/company-news/44331-gilead-presents-follow-up-data-from-zydelig-registrational-studies-in-patients-with-chronic-lymphocytic-leukemia-follicular-lymphoma-and-small-lymphocytic-lymphoma.htm
Skip down to the section titled
Long-Term Data in CLL
, Includes information on Study 116/117 and the boxed warning (safety information) for
idelalisib
: http://www.finances.com/company-news/44331-gilead-presents-follow-up-data-from-zydelig-registrational-studies-in-patients-with-chronic-lymphocytic-leukemia-follicular-lymphoma-and-small-lymphocytic-lymphoma.htm
AussieNeil
Partner
in
CLL Support
10 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Idelalisib is now CDF listed to treat relapsed/refractory CLL through the English Cancer Drugs Fund.
Idelalisib
should be continued to progression. 7.
Idelalisib
should be continued to progression. 7.
HAIRBEAR_UK
Administrator
in
CLL Support
10 years ago
Dr Sharman's survey to assess the CLL community's understanding of new treatments is now closed
Dr Jeff Sharman is curious to understand what people know / think they know about the new drugs Ibrutinib,
Idelalisib
and obinutuzumab. His latest blog was a 10 question survey (now closed) to gain CLL community feedback, the results of which he plans to use to help shape future his blog posts.
Dr Jeff Sharman is curious to understand what people know / think they know about the new drugs Ibrutinib,
Idelalisib
and obinutuzumab. His latest blog was a 10 question survey (now closed) to gain CLL community feedback, the results of which he plans to use to help shape future his blog posts.
AussieNeil
Partner
in
CLL Support
10 years ago
Dr Sharman on Immunotherapy for Indolent (low grade) Lymphoma - includes SLL!
[/i] http://www.cll-nhl.com/2014/09/immunotherapy-for-indolent-low-grade.html The following drugs that should be familiar to us get specific mention: Bendamustine,
Idelalisib
, Iibrutinib, Revlimid, Rituximab and Vincristine.
[/i] http://www.cll-nhl.com/2014/09/immunotherapy-for-indolent-low-grade.html The following drugs that should be familiar to us get specific mention: Bendamustine,
Idelalisib
, Iibrutinib, Revlimid, Rituximab and Vincristine.
AussieNeil
Partner
in
CLL Support
10 years ago
Dr Sharman's Idelalisib (Zydelig) Update based on European experience
[/i] More at: http://www.cll-nhl.com/2014/09/
idelalisib
-zydelig-update.html See also
European Commission Grants Marketing Authorization for Gilead’s Zydelig® (
) for the Treatment of Chronic Lymphocytic Leukemia: https://healthunlocked.com/cllsupport/posts/131165991/european-commission-grants-marketing-authorization-for-gilead
[/i] More at: http://www.cll-nhl.com/2014/09/
idelalisib
-zydelig-update.html See also
European Commission Grants Marketing Authorization for Gilead’s Zydelig® (
) for the Treatment of Chronic Lymphocytic Leukemia: https://healthunlocked.com/cllsupport/posts/131165991/european-commission-grants-marketing-authorization-for-gilead
AussieNeil
Partner
in
CLL Support
10 years ago
FDA Grants Special Protocol Assessment to Phase III Ublituximab/Ibrutinib Study
planned to enroll approximately 330 patients, who will receive ublituximab plus ibrutinib or ibrutinib alone. " More: http://www.onclive.com/web-exclusives/FDA-Grants-Special-Protocol-Assessment-to-Phase-III-UblituximabIbrutinib-Study Watch out for more combination therapies with ibrutinib and
Idelalisib
planned to enroll approximately 330 patients, who will receive ublituximab plus ibrutinib or ibrutinib alone. " More: http://www.onclive.com/web-exclusives/FDA-Grants-Special-Protocol-Assessment-to-Phase-III-UblituximabIbrutinib-Study Watch out for more combination therapies with ibrutinib and
Idelalisib
AussieNeil
Partner
in
CLL Support
10 years ago
Want to avoid chemotherapy or taking an expensive medication forever for your CLL? I may have a clinical trial for you.
Before we had ibrutinib and
idelalisib
and the other TKIs in the pipelines, for those of us wanting to avoid myelosuppressive therapies, we had HDMP +R. Dr.
Before we had ibrutinib and
idelalisib
and the other TKIs in the pipelines, for those of us wanting to avoid myelosuppressive therapies, we had HDMP +R. Dr.
bkoffman
CLL CURE Hero
in
CLL Support
10 years ago
European Commission Grants Marketing Authorization for Gilead’s Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia
Gilead press release European Commission Grants Marketing Authorization for Gilead’s Zydelig® (
Idelalisib
) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma -- First-in-Class Oral Treatment for Two Incurable Blood Cancers -- FOSTER CITY, Calif.
Gilead press release European Commission Grants Marketing Authorization for Gilead’s Zydelig® (
Idelalisib
) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma -- First-in-Class Oral Treatment for Two Incurable Blood Cancers -- FOSTER CITY, Calif.
HAIRBEAR_UK
Administrator
in
CLL Support
10 years ago
Zydelig: The Black Box Warnings for use in CLL
Hi Friends, On my blog (http://bkoffman.blogspot.com), I have commented on the extensive black box warnings on the label for
idelalisib
or ZYDELIG that is a stark contrast to no black box for ibrutinib, not that IMBRUVICA doesn't come with its own set of cautions and concerns.
Hi Friends, On my blog (http://bkoffman.blogspot.com), I have commented on the extensive black box warnings on the label for
idelalisib
or ZYDELIG that is a stark contrast to no black box for ibrutinib, not that IMBRUVICA doesn't come with its own set of cautions and concerns.
bkoffman
CLL CURE Hero
in
CLL Support
10 years ago
UK 'OK to ask' patient empowerment campaign encourages patients to take part in research & FLAIR 1st line CLL trial commences + others.
CALiBRe (
Idelalisib
) is another kinase inhibitor trial which is still in set-up but is due to open this year.
CALiBRe (
Idelalisib
) is another kinase inhibitor trial which is still in set-up but is due to open this year.
HAIRBEAR_UK
Administrator
in
CLL Support
10 years ago
Details and Analysis of the FDA Approved Indications for Idelalisib PLUS Links for Financial Help
First FDA approval of
idelalisib
, then the positive recommendation for approval for
idelalisib
and ibrutinib in the EU, then the surprising FDA approval of ibrutinib in frontline 17p deleted patients.
First FDA approval of
idelalisib
, then the positive recommendation for approval for
idelalisib
and ibrutinib in the EU, then the surprising FDA approval of ibrutinib in frontline 17p deleted patients.
bkoffman
CLL CURE Hero
in
CLL Support
10 years ago
European recommendation for Ibrutinib and Idelalisib
Both Ibrutinib and
Idelalisib
have been recommended for approval by European regulators, paving the way for formal approval in a couple of months. Source: Reuters, 25/07/14. Great news but more work to be done here in the UK to gain approval for the Cancer Drugs Fund and NICE. Watch this space.
Both Ibrutinib and
Idelalisib
have been recommended for approval by European regulators, paving the way for formal approval in a couple of months. Source: Reuters, 25/07/14. Great news but more work to be done here in the UK to gain approval for the Cancer Drugs Fund and NICE. Watch this space.
MaudMarie
in
CLL Support
10 years ago
ASH 2013: Dr. John Pagel Speculates on the Future of CLL Therapies including the late breaking data on Idelalisib
John Pagel Speculates on the Future of CLL (chronic lymphocytic leukemia) Therapies including the late breaking data on
Idelalisib
ASCO is around the corner, but there is still important material to share from ASH.
John Pagel Speculates on the Future of CLL (chronic lymphocytic leukemia) Therapies including the late breaking data on
Idelalisib
ASCO is around the corner, but there is still important material to share from ASH.
bkoffman
CLL CURE Hero
in
CLL Support
10 years ago
3 years on Ibrutinib/Imbruvica and a study involving fasting
Since many of our community members will not have access to the new kinase inhibitors (Ibru/Imbru
Idelalisib
) and must be treated with chemo I thought this case history study on fasting might be worth reading and discussing with your respective Docs. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815756
Since many of our community members will not have access to the new kinase inhibitors (Ibru/Imbru
Idelalisib
) and must be treated with chemo I thought this case history study on fasting might be worth reading and discussing with your respective Docs. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815756
ThreeWs
in
CLL Support
10 years ago
CT scan series part 10 - Clinical Trial CT scan Context
Ibrutinib and
Idelalisib
are two drugs that illustrate the difficulty for obtaining that evidence. These two drugs initially cause an increase of cancer cells in the peripheral blood, unlike standard chemo and mAbs that show an immediate decrease as the cells are killed off.
Ibrutinib and
Idelalisib
are two drugs that illustrate the difficulty for obtaining that evidence. These two drugs initially cause an increase of cancer cells in the peripheral blood, unlike standard chemo and mAbs that show an immediate decrease as the cells are killed off.
ThreeWs
in
CLL Support
10 years ago
ASH 2013: INTERVIEW WITH DR. FURMAN RE: IDELALISIB
Furman who was the lead on the
idelalisIb
trial that was a late breaking abstract at ASH 2013. I have also includes links to the abstract and related subjects.
Furman who was the lead on the
idelalisIb
trial that was a late breaking abstract at ASH 2013. I have also includes links to the abstract and related subjects.
bkoffman
CLL CURE Hero
in
CLL Support
10 years ago
34 months on a Phase I-b Clinical Trial for Ibrutinib. A day of monitoring at OSU medical center with CLL specialist Dr. John Byrd
A guy passes by interested in our conversation and he is on
Idelalisib
and is doing well. Another lady with a bizarre presentation of low ALC and platelets in the 30s is on W&W and another fellow diagnosed at 34 is just getting his first dose of Revlimid.
A guy passes by interested in our conversation and he is on
Idelalisib
and is doing well. Another lady with a bizarre presentation of low ALC and platelets in the 30s is on W&W and another fellow diagnosed at 34 is just getting his first dose of Revlimid.
ThreeWs
in
CLL Support
10 years ago
Dr Richard Furman reports on Idelalisib and Rituximab Phase III study outcomes at ASH2013
Richard Furman on Avoiding Chemotherapy with
Idelalisib
) Also see the Patient Power interview of Dr Peter Hillmen taken in August 2013 at the iwCLL in Collogne Germany on his ideas on the role of
Idelalisib
https://healthunlocked.com/cllsupport/posts/130295905/dr-peter-hillmen-of-leeds-uk-discusses-the-place-for-
idelalisib
-in-cll-treatment-patient-power-video
Richard Furman on Avoiding Chemotherapy with
Idelalisib
) Also see the Patient Power interview of Dr Peter Hillmen taken in August 2013 at the iwCLL in Collogne Germany on his ideas on the role of
Idelalisib
https://healthunlocked.com/cllsupport/posts/130295905/dr-peter-hillmen-of-leeds-uk-discusses-the-place-for-
idelalisib
-in-cll-treatment-patient-power-video
AussieNeil
Partner
in
CLL Support
11 years ago
1
...
5
6
7
8
Next page
Filter results
Clear filters
Posted in
All communities
CLL Support
132 results
Non Hodgkin's Lymphoma Friends
6 results
Advanced Prostate Cancer
1 result
View top 10 communities
Sort by
Most Relevant
Newest